Aug. 9 Clinical Quick Takes: Lexicon's one-year Zynquista follow-up; plus 89bio and TopiVert
Biomarker data lift Lexicon
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) rose $0.25 (20%) to $1.53 Friday after reporting pooled 52-week follow-up data from two Phase III trials showing that Zynquista sotagliflozin lowered biomarker levels of chronic kidney disease and showed potential to reduce cardiovascular risk in Type I diabetics. The readouts include changes in estimated glomerular filtration rate (eGFR), hematocrit, serum albumin and serum uric acid levels and systolic and diastolic blood pressure. The dual inhibitor of SGLT1 and SGLT2 is approved in the EU as an adjunct to insulin to improve blood sugar control in adults with Type I diabetes.
89bio starts proof-of-concept NASH trial
89bio Ltd. (San Francisco, Calif.) began screening patients for a Phase Ib/II trial that will evaluate BIO89-100 in patients with non-alcoholic steatohepatitis and individuals with non-alcoholic fatty liver disease at high risk for NASH. The trial will enroll 83 patients and evaluate safety, PK/PD and liver fat and biomarker markers. The company plans to develop the long-acting glycopegylated analog of FGF21 as monotherapy or as a backbone for a combination therapy (see "89bio: Standing Out in the NASH Crowd")...